Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Rivastigmine Tartrate

&times

Overview

What is Rivastigmine Tartrate?



What does Rivastigmine Tartrate look like?



What are the available doses of Rivastigmine Tartrate?

Sorry No records found.

What should I talk to my health care provider before I take Rivastigmine Tartrate?

Sorry No records found

How should I use Rivastigmine Tartrate?


What interacts with Rivastigmine Tartrate?

Sorry No Records found


What are the warnings of Rivastigmine Tartrate?

Gastrointestinal Adverse Reactions

Rivastigmine Tartrate Capsules

use is associated with significant gastrointestinal adverse reactions, including nausea and vomiting, anorexia, and weight loss. For this reason, patients should always be started at a dose of 1.5 mg BID and titrated to their maintenance dose. If treatment is interrupted for longer than several days, treatment should be reinitiated with the lowest daily dose (see ) to reduce the possibility of severe vomiting and its potentially serious sequelae (e.g., there has been one postmarketing report of severe vomiting with esophageal rupture following inappropriate reinitiation of treatment with a 4.5 mg dose after 8 weeks of treatment interruption.)

Array

In the controlled clinical trials, 47% of the patients treated with

Rivastigmine Tartrate Capsules dose in the therapeutic range of 6

to

12 mg/day (n=1189) developed nausea (compared with 12% in placebo). A total of 31% of

Rivastigmine Tartrate Capsules -treated patients developed at least one episode of vomiting (compared with 6% for placebo). The rate of vomiting was higher during the titration phase (24% vs. 3% for placebo) than in the maintenance phase (14% vs. 3% for placebo). The rates were higher in women than men. Five percent of patients discontinued for vomiting, compared to less than 1% for patients on placebo. Vomiting was severe in 2% of Rivastigmine Tartrate Capsules -treated patients and was rated as mild or moderate each in 14% of patients. The rate of nausea was higher during the titration phase (43% vs. 9% for placebo) than in the maintenance phase (17% vs. 4% for placebo).

Array

In the controlled trials, approximately 26% of women on high doses of

Rivastigmine Tartrate Capsules (greater than 9 mg/day) had weight loss equal to or greater than 7% of their baseline weight compared to 6% in the placebo-treated patients. About 18% of the males in the high dose group experienced a similar degree of weight loss compared to 4% in placebo-treated patients. It is not clear how much of the weight loss was associated with anorexia, nausea, vomiting, and the diarrhea associated with the drug.

Array

Array

Array

Anesthesia

Cardiovascular Conditions

Genitourinary

Neurological Conditions

Seizures:

Pulmonary Conditions


What are the precautions of Rivastigmine Tartrate?

Information for Patients and Caregivers

Drug-Drug Interactions

Array

Array

Array

in vitro

Array

Array

Array

Array

Array

Carcinogenesis, Mutagenesis, Impairment of Fertility

in vitro

in vitro

in vivo

Pregnancy

Pregnancy Category B:

Nursing Mothers

Pediatric Use


What are the side effects of Rivastigmine Tartrate?

Dementia of the Alzheimer's type

Adverse Events Leading to Discontinuation

Most Frequent Adverse Clinical Events Seen in Association with the Use of Rivastigmine Tartrate Capsules

Array

Array

Table 1. Most Frequent Adverse Events Leading to Withdrawal from Clinical Trials during Titration and Maintenance in Patients Receiving 6 to 12 mg/day Rivastigmine Tartrate Capsules Using a Forced Dose Titration
Study PhaseTitrationMaintenanceOverall
Event/% DiscontinuingPlacebo(n=868) Rivastigmine Tartrate Capsules≥6 to 12 mg/day(n=1189) Placebo(n=788) Rivastigmine Tartrate Capsules≥6 to 12 mg/day(n=987) Placebo(n=868) Rivastigmine Tartrate Capsules≥6 to 12 mg/day(n=1189)
Nausea 8 1 1 8
Vomiting 4 1 5
Anorexia 0 2 1 3
Dizziness 2 1 2
Table 2. Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Rivastigmine Tartrate Capsules (6 to 12 mg/day) and at a Higher Frequency than Placebo-treated Patients
Body System/Adverse EventPlacebo(n=868)Rivastigmine Tartrate Capsules(6 to 12 mg/day)(n=1189)
Percent of Patients with any Adverse Event79 92
  12   43
  95222   1096533
Cardiovascular Disorders, General   2   3
Central and Peripheral Nervous System   111231   211754
  12611364421   47311917139542
  774332   986543
Resistance Mechanism Disorders   6   7
Respiratory System   3   4


Dementia Associated with Parkinson's disease

Adverse Events leading to discontinuation

Array

Most Frequent Adverse Clinical Events Seen in Association with the Use of Rivastigmine Tartrate Capsules

Adverse Events Reported in Controlled Trials

Table 3. Adverse Events Reported in the Single Controlled Clinical Trial in at Least 2% of Patients Receiving Rivastigmine Tartrate Capsules (3 to 12 mg/day) and at a Higher Frequency than Placebo-treated Patients
Body System/Adverse Event Placebo Rivastigmine Tartrate Capsules
(n=179)
Percent of Patients with any Adverse Event 71 84
Gastrointestinal disorders    
Nausea 11 29
Vomiting 2 17
Diarrhea 4 7
Upper abdominal pain 1 4
General Disorders and administrative site conditions    
Fatigue 3 4
Asthenia 1 2
Metabolism and nutritional disorders    
Anorexia 3 6
Dehydration 1 2
Nervous system Disorders    
Tremor 4 10
Dizziness 1 6
Headache 3 4
Somnolence 3 4
Parkinson’s disease (worsening) 1 3
Parkinsonism 1 2
Psychiatric Disorders    
Anxiety 1 4
Insomnia 2 3


Other Adverse Events Observed During Clinical Trials

Dementia of the Alzheimer's Type

Array

Autonomic Nervous System:

Infrequent:

 

Body as a Whole:

Frequent:

Infrequent

 

Cardiovascular System:

Frequent:

 

Central and Peripheral Nervous System:

Frequent:

Infrequent:

 

Endocrine System:

Infrequent:

Gastrointestinal System:

Frequent:

Infrequent:

 

Hearing and Vestibular Disorders

Frequent:

 

Heart Rate and Rhythm Disorders:

Frequent:

Infrequent:

 

Liver and Biliary System Disorders:

Infrequent:

Metabolic and Nutritional Disorders:

Frequent:

Infrequent:

 

Musculoskeletal Disorders:

Frequent:

Infrequent:

 

Myo-, Endo-, Pericardial and Valve Disorders:

Frequent:

 

Platelet, Bleeding, and Clotting Disorders:

Frequent:

Infrequent:

 

Psychiatric Disorders:

Frequent:

Infrequent:

Red Blood Cell Disorders:

Frequent:

Infrequent:

 

Reproductive Disorders (Female & Male):

Infrequent:

Resistance Mechanism Disorders:

Infrequent:

 

Respiratory System:

Infrequent:

 

Skin and Appendages:

Frequent:

Infrequent:

 

Special Senses:

Infrequent:

Urinary System Disorders:

Frequent:

Infrequent:

Vascular (extracardiac) Disorders:

Infrequent:

Vision Disorders:

Frequent:

Infrequent:

White Cell and Resistance Disorders:

Infrequent:

Array

Array

Frequent:

Infrequent:

Array

Frequent:

Infrequent:

Array

Infrequent:

Array

Frequent:

Infrequent:

Array

Frequent:

Infrequent:

Array

Infrequent:

Array

Infrequent:

Array

Frequent:

  Infrequent:

Array

Frequent:

Infrequent:

Array

Infrequent:

Array

Frequent:

Infrequent:

Array

Infrequent:

Array

Infrequent:

Array

Infrequent:

Post-Introduction Reports

Skin and Appendages:


What should I look out for while using Rivastigmine Tartrate?

Sorry No records found


What might happen if I take too much Rivastigmine Tartrate?

Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

As Rivastigmine Tartrate Capsule has a short plasma half-life of about one hour and a moderate duration of acetylcholinesterase inhibition of 8 to 10 hours, it is recommended that in cases of asymptomatic overdoses, no further dose of Rivastigmine Tartrate Capsules should be administered for the next 24 hours.

As in any case of overdose, general supportive measures should be utilized.  Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when co-administered with quaternary anticholinergics such as glycopyrrolate. Due to the short half-life of Rivastigmine Tartrate Capsules, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose.

In overdoses accompanied by severe nausea and vomiting, the use of antiemetics should be considered. In a documented case of a 46 mg overdose with Rivastigmine Tartrate Capsules, the patient experienced vomiting, incontinence, hypertension, psychomotor retardation, and loss of consciousness. The patient fully recovered within 24 hours and conservative management was all that was required for treatment.


How should I store and handle Rivastigmine Tartrate?

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx onlyESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx onlyESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx onlyESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx onlyESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx onlyESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Full Strength light green, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “231” on other. Contains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength in bottles of 100.ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE TABLETS Half Strength light blue, capsule-shaped, film-coated oral tablets, debossed “SYNTHO” on one side and “230” on other. Contains 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.Store at 20°- 25°C (68°- 77°F); excursions permitted to 15°- 30°C (59° - 86°F). [See USP Controlled Room Temperature.]Rx only


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).